92 related articles for article (PubMed ID: 17641543)
1. Effect of darbepoetin alfa on physical function in patients undergoing surgery for colorectal cancer. A randomized, double-blind, placebo-controlled study.
Norager CB; Jensen MB; Madsen MR; Qvist N; Laurberg S
Oncology; 2006; 71(3-4):212-20. PubMed ID: 17641543
[TBL] [Abstract][Full Text] [Related]
2. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
4. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C
Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
[TBL] [Abstract][Full Text] [Related]
5. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
[TBL] [Abstract][Full Text] [Related]
6. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
Agnihotri P; Telfer M; Butt Z; Jella A; Cella D; Kozma CM; Ahuja M; Riaz S; Akamah J
J Am Geriatr Soc; 2007 Oct; 55(10):1557-65. PubMed ID: 17697104
[TBL] [Abstract][Full Text] [Related]
7. Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial.
Courneya KS; Jones LW; Peddle CJ; Sellar CM; Reiman T; Joy AA; Chua N; Tkachuk L; Mackey JR
Oncologist; 2008 Sep; 13(9):1012-20. PubMed ID: 18779540
[TBL] [Abstract][Full Text] [Related]
8. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
[TBL] [Abstract][Full Text] [Related]
10. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Smith RE; Aapro MS; Ludwig H; Pintér T; Smakal M; Ciuleanu TE; Chen L; Lillie T; Glaspy JA
J Clin Oncol; 2008 Mar; 26(7):1040-50. PubMed ID: 18227526
[TBL] [Abstract][Full Text] [Related]
11. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
13. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
14. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
[TBL] [Abstract][Full Text] [Related]
15. Quality of life improvements in dialysis patients receiving darbepoetin alfa.
Fukuhara S; Akizawa T; Morita S; Koshikawa S;
Ther Apher Dial; 2008 Feb; 12(1):72-7. PubMed ID: 18257816
[TBL] [Abstract][Full Text] [Related]
16. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
18. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
[TBL] [Abstract][Full Text] [Related]
19. Association of anemia correction with health related quality of life in patients not on dialysis.
Alexander M; Kewalramani R; Agodoa I; Globe D
Curr Med Res Opin; 2007 Dec; 23(12):2997-3008. PubMed ID: 17958944
[TBL] [Abstract][Full Text] [Related]
20. Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue.
Stull DE; Vernon MK; Legg JC; Viswanathan HN; Fairclough D; Revicki DA
Contemp Clin Trials; 2010 Mar; 31(2):172-9. PubMed ID: 20060499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
